Patents Represented by Attorney, Agent or Law Firm Gregory A. Cox
-
Patent number: 8257704Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.Type: GrantFiled: June 21, 2011Date of Patent: September 4, 2012Assignee: Eli Lilly and CompanyInventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
-
Patent number: 8110191Abstract: Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.Type: GrantFiled: October 21, 2010Date of Patent: February 7, 2012Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Chi-Kin Chow, Ling Liu, Jirong Lu, Jonathan Wendell Tetreault, Ying Tang
-
Patent number: 8066995Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bond density, or for the treatment of various disorders in mammalian and avian species, X17251.Type: GrantFiled: November 3, 2009Date of Patent: November 29, 2011Assignee: Eli Lilly and CompanyInventors: Julian Davies, Bryan Edward Jones, Andrew Ihor Korytko, Pamela Jean Mitchell, Rosamund Carol Smith, Linda O'Bryan (Nee Tobias), Rong Wang
-
Patent number: 8063188Abstract: Monoclonal anti-myostatin antibodies that preferentially bind myostatin over GDF-11, have strong binding affinity to myostatin and are resistant to chemical degradation. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment or prevention of various disorders in mammalian and avian species.Type: GrantFiled: August 23, 2007Date of Patent: November 22, 2011Assignee: Eli Lilly and CompanyInventors: Robert Owen Sayers, Lihua Huang
-
Patent number: 7598350Abstract: The present invention provides a fully human antibody that binds human EGFR with affinity comparable to or higher than IMC-C225, and that neutralizes activation of EGFR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chains antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells and animals that encode and express these antibodies. The invention further provides a method for neutralizing activation of EGFR, treating in a mammal with neoplastic growth and non-cancerous hyperproliferative diseases using the antibodies alone or in combination with other agents.Type: GrantFiled: March 21, 2005Date of Patent: October 6, 2009Assignee: ImClone LLCInventors: Meilin Liu, Zhenping Zhu
-
Patent number: 7498308Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.Type: GrantFiled: May 18, 2006Date of Patent: March 3, 2009Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican
-
Patent number: 7452966Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: GrantFiled: June 10, 2004Date of Patent: November 18, 2008Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick
-
Patent number: 7317089Abstract: Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b(e.g., KD=10?8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.Type: GrantFiled: August 15, 2002Date of Patent: January 8, 2008Assignee: Eli Lilly and CompanyInventor: Kristine Kay Kikly
-
Patent number: 7271149Abstract: The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.Type: GrantFiled: November 29, 2001Date of Patent: September 18, 2007Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Radmila Micanovic, Sheng-Hung Rainbow Tschang
-
Patent number: 7232879Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.Type: GrantFiled: January 30, 2004Date of Patent: June 19, 2007Assignee: Eli Lilly and CompanyInventors: John A. Galloway, James A. Hoffmann
-
Patent number: 7223728Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.Type: GrantFiled: October 6, 2003Date of Patent: May 29, 2007Assignee: Eli Lilly and CompanyInventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Louis Vignati
-
Patent number: 7211557Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.Type: GrantFiled: May 5, 2003Date of Patent: May 1, 2007Assignee: Eli Lilly and CompanyInventors: Richard DiMarchi, Suad Efendic
-
Patent number: 7199217Abstract: The present invention encompasses a GLP-1 analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.Type: GrantFiled: November 30, 2001Date of Patent: April 3, 2007Assignee: Eli Lilly and CompanyInventors: Richard Dennis DiMarchi, Rohn Lee Millican, Jr., Wolfgang Glaesner
-
Patent number: 7144863Abstract: The present invention encompasses compositions wherein a GLP-1 compound is complexed with a basic polypeptide. The compositions provide a prolonged duration of action and can be administered by the pulmonary route.Type: GrantFiled: May 21, 2002Date of Patent: December 5, 2006Assignee: Eli Lilly and CompanyInventors: Michael Rosario DeFelippis, Henry Acken Havel, Kenneth F. Mace, Kingman Ng, Virender Kumar Sarin
-
Patent number: 7101843Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.Type: GrantFiled: August 14, 2002Date of Patent: September 5, 2006Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Lianshan Zhang
-
Patent number: 7084243Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed.Type: GrantFiled: June 1, 2001Date of Patent: August 1, 2006Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican
-
Patent number: 6747006Abstract: This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.Type: GrantFiled: April 12, 2001Date of Patent: June 8, 2004Assignee: Eli Lilly and CompanyInventor: Suad Efendic
-
Patent number: 6720407Abstract: The claimed invention relates to a method of administering glucagon-like peptide-1 molecules by inhalation, a method for treating diabetes by administering glucagon-like peptide-1 molecules by inhalation, and a method for treating hyperglycemia by administering glucagon-like peptide-1 molecules by inhalation.Type: GrantFiled: August 26, 1999Date of Patent: April 13, 2004Assignee: Eli Lilly and CompanyInventors: Benjamin Lee Hughes, Ronald Keith Wolff
-
Patent number: 6703365Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.Type: GrantFiled: April 17, 2002Date of Patent: March 9, 2004Assignee: Eli Lilly and CompanyInventors: John A. Galloway, James A. Hoffmann
-
Patent number: 6388053Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.Type: GrantFiled: October 12, 2001Date of Patent: May 14, 2002Assignee: Eli Lilly and CompanyInventors: John A. Galloway, James A. Hoffmann